Inteligex has graduated from Creative Destruction Labs (CDL) Toronto. CDL is a nonprofit organization that delivers an objectives-based program for massively scalable, seed-stage, science- and technology-based companies. The program provided Inteligex with a year of mentorship with business advisors, chief scientists and angel investors, as well as opportunities to raise capital.
Inteligex Founder and President Dr. Michael Fehlings was invited to be the inaugural guest for the recently launched Optimal NeuroSpine Podcast. In this interview, Dr. Fehlings discusses recent advances in spinal cord injury, the importance of translational research, and the promise of stem cell therapy.
Inteligex Inc. is seeking to hire a Director for its Cell and Gene Therapy and GMP Manufacturing. Apply Here The Director of Cell and Gene Therapy will be expected to provide comprehensive technical and scientific guidance relating to clinical and product development, GMP manufacturing, and regulatory compliance in the area of cell and gene therapies.
The ONtrepreneurs (Ontario Neurotech Entrepreneurs) Program is Canada’s single largest award that catalyzes early stage entrepreneurs to commercialize brain-related technologies. Dr Chris Ahuja (Inteligex CEO) became an OBI 2020 ONtrepreneur to accelerate the commercialization of the stem cell work. Inteligex has received a $50,000 non-dilutive fund from OBI for being a 2020 ONtrepreneur.
Inteligex claimed 1st Place in the Early Stage Category of the 2020 RBC Prize for Innovation & Entrepreneurship awards. Ten cutting-edge University of Toronto student startup teams competed in the RBC Prize for Innovation & Entrepreneurship – the largest pitch competition of the year as part of U of T Entrepreneurship Week. The annual RBC […]